The stock of Passage Bio Inc (PASG) has gone up by 19.56% for the week, with a -11.38% drop in the past month and a 5.07% rise in the past quarter. The volatility ratio for the week is 12.29%, and the volatility levels for the past 30 days are 11.30% for PASG. The simple moving average for the last 20 days is -1.79% for PASG stock, with a simple moving average of -24.87% for the last 200 days.
Is It Worth Investing in Passage Bio Inc (NASDAQ: PASG) Right Now?
The 36-month beta value for PASG is also noteworthy at 1.64. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PASG is 53.21M, and at present, short sellers hold a 3.35% of that float. The average trading volume of PASG on July 01, 2025 was 280.09K shares.
PASG) stock’s latest price update
Passage Bio Inc (NASDAQ: PASG)’s stock price has increased by 20.90 compared to its previous closing price of 0.33. However, the company has seen a 19.56% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones. “We are pleased to share updated data highlighting the promise of PBFT02 for the frontotemporal dementia community.
Analysts’ Opinion of PASG
Many brokerage firms have already submitted their reports for PASG stocks, with Wedbush repeating the rating for PASG by listing it as a “Outperform.” The predicted price for PASG in the upcoming period, according to Wedbush is $4 based on the research report published on November 29, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PASG reach a price target of $7. The rating they have provided for PASG stocks is “Buy” according to the report published on September 03rd, 2024.
PASG Trading at 9.44% from the 50-Day Moving Average
After a stumble in the market that brought PASG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.90% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PASG starting from ORBIMED ADVISORS LLC, who sale 231,600 shares at the price of $0.35 back on Jun 24 ’25. After this action, ORBIMED ADVISORS LLC now owns 6,418,400 shares of Passage Bio Inc, valued at $81,060 using the latest closing price.
ORBIMED ADVISORS LLC, the 10% Owner of Passage Bio Inc, sale 213,257 shares at $0.33 during a trade that took place back on Jun 26 ’25, which means that ORBIMED ADVISORS LLC is holding 6,066,343 shares at $70,375 based on the most recent closing price.
Stock Fundamentals for PASG
The total capital return value is set at -1.01. Equity return is now at value -83.73, with -56.03 for asset returns.
Based on Passage Bio Inc (PASG), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -1.71.
Currently, EBITDA for the company is -61.69 million with net debt to EBITDA at 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.
Conclusion
In summary, Passage Bio Inc (PASG) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
